The main purpose of this study is to find out whether treatment to prevent kidney rejection with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result in less delayed graft function or "sleepy kidney" after transplant than that seen in patients who get tacrolimus as their main drug to prevent rejection instead of belatacept. The investigators will also look at whether patients who get belatacept have the same, lesser or more problems that those who get tacrolimus.

Purpose

A trial to determine if eculizumab is safe and could be used to prevent Delayed Graft Function after kidney transplantation.

Description

Delayed Graft Function (DGF) is an early complication of organ transplantation, which consists of the failure of an organ to function when it is initially transplanted.  Most often DGF results from ischemia/reperfusion injury (IRI), a complex pathological process that is a consequence of organ preservation.

The purpose of the study is to determine if eculizumab is safe and could be used following desensitization therapy to prevent a condition called antibody mediated rejection (AMR).

Closed to patient enrollment.